All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On August 30, 2021, it was announced that the U.S Food and Drug Administration (FDA) has cleared an Investigational New Drug application for P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma (RRMM).
P-BCMA-ALLO1 is a fully allogeneic chimeric antigen receptor T-cell product designed to target B-cell maturation antigen (BCMA). The agent demonstrated encouraging antitumor responses and cytokine secretion both in vivo and in vitro. The manufacturing protocol involves a ‘booster molecule’ that facilitates expansion, significantly increases product yield, and reduces cost.
This decision from the FDA permits patient enrollment to a phase I study (NCT04960579) evaluating P-BCMA-ALLO1 for the treatment of patients with RRMM following treatment with a proteasome inhibitor, immunomodulatory agent, and anti-CD38 therapy. The study will follow a 3×3 dose-escalation design, with patients first receiving chemotherapy-based conditioning and an initial single dose of the study drug. Once acceptable safety and tolerability has been confirmed, patients can continue with additional doses of P-BCMA-ALLO1. The study design grants the investigation of alternative dosing regimens and patient enrollment is set to commence in late 2021.
If successful in clinical trials, P-BCMA-ALLO1 could offer an effective, accessible, and cost-effective treatment approach to RRMM.
Poseida Therapeutics. Poseida Therapeutics announces FDA clearance of investigational new drug application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for relapsed/refractory multiple myeloma. https://investors.poseida.com/news-releases/news-release-details/poseida-therapeutics-announces-fda-clearance-investigational-new. Published Aug 30, 2021. Accessed Sept 1, 2021.
Subscribe to get the best content related to multiple myeloma delivered to your inbox